僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Ladiratuzumab （hLIV22） is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE （HY-15162） to compose SGN-LIV1A, an antibody-drug conjugate （ADC）. Ladiratuzumab can be used for research of breast cancer